Skip to main content

Health condition · Clinically reviewed

Craniopharyngioma, a benign tumour with life-changing effects, treated in specialist UK centres.

Rare, WHO grade 1, but sits over the pituitary and hypothalamus. Modern care blends specialist surgery, proton beam therapy, hormone replacement and, for papillary disease, BRAF-targeted therapy.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, NHS specialist commissioned services, WHO 2021 CNS classification and peer-reviewed neuro-oncology sources.

  • 03

    Current for 2026

    Reflects modern UK practice including BRAF/MEK targeted therapy, proton beam therapy and setmelanotide for hypothalamic obesity.

Key facts

Craniopharyngioma at a glance.

The essentials, in plain English. Two subtypes, a difficult location and a treatment landscape that has changed significantly in the last decade.

  • What it is

    A rare benign (WHO grade 1) but locally aggressive suprasellar tumour derived from embryological remnants of Rathke's pouch.

  • Who gets it

    Bimodal age distribution. Children 5 to 14 years and adults in their 50s to 70s. Around 1 to 3 per cent of all intracranial tumours and 5 to 10 per cent of paediatric brain tumours.

  • Two subtypes

    Adamantinomatous (around 90 per cent, mostly children, CTNNB1 mutation, calcified and cystic) and papillary (adults, BRAF V600E mutation in around 95 per cent, solid).

  • Where it sits

    Sellar and suprasellar region, closely involving the hypothalamus, optic chiasm, pituitary gland and third ventricle.

  • How it presents

    Headache, visual field loss (classically bitemporal hemianopia), hormone deficiencies, diabetes insipidus and hypothalamic obesity.

  • How it is treated

    Specialist surgery (transsphenoidal or transcranial), radiotherapy including proton beam for children, hormone replacement and BRAF/MEK inhibitors for papillary disease.

Why this guide matters

A tumour where function matters as much as removal.

Craniopharyngioma is technically benign but sits in one of the most delicate parts of the brain. The three ideas below shape everything else on this page.

  • Location dictates strategy

    The tumour hugs the hypothalamus and optic chiasm. Modern care often accepts a small residual tumour to protect vision, memory, hormones and metabolism.

  • Radiotherapy has evolved

    Stereotactic radiosurgery and proton beam therapy make it possible to control residual disease with far less collateral damage, particularly in children.

  • Molecular biology is treatment

    Papillary craniopharyngioma with a BRAF V600E mutation can shrink dramatically with dabrafenib and trametinib - sometimes before surgery is even needed.

How the diagnosis is made

From first symptoms to a specialist plan.

The pathway a UK GP, endocrinologist or neuro-oncology team will normally follow so you know what to expect and why.

  1. 01

    Assessing

    Clinical history and examination

    A careful history of headache, vision, growth, puberty, thirst, weight change, mood and cognition, plus a focused neurological and endocrine examination.

  2. 02

    Assessing

    MRI with gadolinium

    The gold standard investigation. Shows a suprasellar mass with solid, cystic and calcified components, hydrocephalus, chiasmal compression and hypothalamic involvement (Puget grade I to III).

  3. 03

    Assessing

    CT for calcification

    Complements MRI by showing the calcification pattern that is characteristic of adamantinomatous disease.

  4. 04

    Confirming

    Full endocrine workup

    Cortisol, ACTH, TSH, free T4, prolactin, LH, FSH, testosterone or oestrogen, growth hormone, IGF-1, paired serum sodium and urinary osmolality, with a water deprivation test if diabetes insipidus is suspected.

  5. 05

    Confirming

    Ophthalmology assessment

    Formal visual fields (Humphrey or Goldmann), acuity, colour vision and fundoscopy to document chiasmal compression before and after treatment.

  6. 06

    Confirming

    Neuropsychology baseline

    Baseline memory, attention, executive function and mood testing so that treatment effects can be measured against a clear starting point.

  7. 07

    Planning

    Specialist MDT review

    Discussion at a paediatric or adult neuro-oncology MDT covering skull base neurosurgery, endocrinology, radiation oncology and specialist commissioned centres across the UK.

Typical timeline: urgent imaging within days, full workup and MDT decision within a few weeks.

Symptoms

What craniopharyngioma actually feels like.

A mix of mass effect on the visual pathway, hormone failure and hypothalamic dysfunction. Some tumours are found incidentally on scans done for another reason.

  • Persistent headache

    Often a morning headache that worsens over weeks or months, sometimes with nausea and vomiting from raised intracranial pressure or hydrocephalus.

  • Bitemporal hemianopia

    The classic visual field defect from chiasmal compression. Patients bump into things on both sides or miss traffic in their peripheral vision.

  • Reduced acuity and papilloedema

    Blurred vision, colour desaturation and swollen optic discs on fundoscopy suggest advanced compression that needs urgent review.

  • Growth failure in children

    Falling off the growth centiles, delayed or arrested puberty and slow tempo often precede other symptoms by years.

  • Diabetes insipidus

    Excessive thirst, high-volume dilute urine and disturbed sleep. Reflects damage to the posterior pituitary and hypothalamus.

  • Hypopituitarism

    Fatigue, cold intolerance, low libido, amenorrhoea, adrenal crises and hyperprolactinaemia from stalk effect. Any combination of anterior pituitary hormones can fail.

  • Hypothalamic obesity

    Rapid, severe and progressive weight gain that is refractory to lifestyle change, alongside temperature, sleep, thirst and behavioural changes.

  • Red flag - vision loss or drowsiness

    New or rapidly worsening vision, reduced consciousness, severe headache or vomiting need same-day neurosurgical assessment.

Treatment

How craniopharyngioma is treated in the UK.

Specialist surgery, tailored radiotherapy including proton beam, lifelong hormone replacement, and BRAF-targeted therapy for papillary disease. Care is centralised in commissioned UK centres such as Queen Square, King\'s, Cambridge, Oxford, Bristol, Newcastle, Sheffield, Manchester, Great Ormond Street, Alder Hey and Birmingham Children\'s.

  • Transsphenoidal surgery

    Minimally invasive endoscopic approach through the nose. Preferred for sellar and small suprasellar disease and delivered in specialist UK skull base centres.

  • Transcranial surgery

    Open craniotomy for larger tumours with significant suprasellar or hypothalamic extension. More invasive with higher morbidity but sometimes unavoidable.

  • Planned partial resection

    Gross total resection is often impossible without hypothalamic injury. A limited resection followed by radiotherapy is increasingly preferred to preserve function.

  • External beam radiotherapy

    Around 54 Gy in fractions for residual, recurrent or inoperable disease. Delivered at specialist radiation oncology centres.

  • Stereotactic radiosurgery

    Gamma Knife or CyberKnife for small, well-defined residual or recurrent nodules. See our guide to gamma knife radiosurgery for detail.

  • Proton beam therapy

    Critical for children. Reduces dose to hypothalamus and hippocampus, preserves neurocognition and endocrine function and lowers the risk of secondary tumours. Delivered at UCLH and The Christie.

  • Targeted BRAF and MEK therapy

    For papillary craniopharyngioma with BRAF V600E, dabrafenib and trametinib can dramatically shrink tumours and are increasingly used as neoadjuvant therapy.

  • Hormone replacement and DDAVP

    Lifelong replacement tailored to each deficient axis. Hydrocortisone, thyroxine, growth hormone, sex hormones and desmopressin for diabetes insipidus.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, WHO tumour classification and specialist society consensus, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your neuro-oncology team, endocrinologist or GP knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • WHO Classification of Tumours of the Central Nervous System, 5th edition (2021).

  • NHS England. Specialised neuro-oncology and pituitary services (adult and paediatric).

  • Society for Endocrinology (UK) and Pituitary Society. Guidance on hypopituitarism and diabetes insipidus.

  • European Society for Paediatric Endocrinology (ESPE). Consensus on hypothalamic obesity and childhood craniopharyngioma.

  • NICE guidance and evidence reviews on brain and CNS tumours, radiotherapy and proton beam therapy.

Red flags

When craniopharyngioma needs urgent attention.

Most of the day-to-day management is planned. These are the situations that are not - and where a specialist opinion is needed straight away.

  • Rapidly worsening vision

    Sudden or fast progressive visual loss suggests acute chiasmal or nerve compression and needs same-day neurosurgical review.

  • Acute hydrocephalus

    Severe headache, vomiting, drowsiness or unsteadiness may reflect obstruction of the third ventricle. An emergency.

  • Adrenal crisis

    Collapse, low blood pressure, hyponatraemia or vomiting in someone with known or suspected hypopituitarism. Needs immediate intravenous hydrocortisone.

  • Undiagnosed diabetes insipidus

    Extreme thirst with high urine output and rising sodium is dangerous, especially in children and after surgery. Urgent endocrine input.

  • Post-operative deterioration

    New confusion, seizures, CSF leak, meningitis features or sodium swings after transsphenoidal or transcranial surgery need urgent specialist review.

  • Severe hypothalamic obesity

    Rapid, progressive weight gain with metabolic complications warrants specialist obesity and endocrine input, not repeated lifestyle advice.

  • Behavioural or personality change

    New rage attacks, apathy, memory failure or disinhibition can reflect hypothalamic involvement and deserve prompt reassessment.

  • New neurological signs

    New weakness, cranial nerve palsy or seizures need urgent imaging to look for recurrence, cyst enlargement or hydrocephalus.

  • Vaccination or steroid stress cover

    Patients on steroid replacement need sick-day rules and stress dosing. Missed cover can trigger crisis.

Living with it

A lifelong condition, but a manageable one.

Four things make the biggest day-to-day difference: a specialist team that knows you, reliable hormone replacement, honest attention to hypothalamic obesity, and using the UK charities that exist to help.

A quiet reminder

You are not managing this alone.

Rehabilitation, neuropsychology, educational support and peer networks are part of the treatment, not extras. Ask.

  1. 01 Team

    Stay linked to a specialist centre

    Craniopharyngioma is a lifelong condition. A named endocrinologist and neuro-oncology team, with regular MRI surveillance, catch problems early.

  2. 02 Hormones

    Never miss steroid or DDAVP doses

    Hydrocortisone and desmopressin are life-sustaining. Carry a steroid card, learn sick-day rules and keep emergency injections at home if advised.

  3. 03 Weight

    Take hypothalamic obesity seriously

    This is a biological consequence of the tumour, not a lifestyle failure. Ask about GLP-1 therapies, setmelanotide access and specialist obesity services.

  4. 04 Support

    Use the UK charities

    The Brain Tumour Charity, Children with Cancer UK and the Pituitary Foundation offer information, peer support and help navigating school, work and benefits.

Frequently asked

Everything we get asked about craniopharyngioma.

Quick answers on subtypes, surgery, radiotherapy, targeted therapy and hypothalamic obesity.

  • What is a craniopharyngioma?

    A rare benign brain tumour that grows in the suprasellar region from embryological remnants of Rathke's pouch. It is classified as WHO grade 1 but behaves in a locally aggressive way because it sits so close to the hypothalamus, optic chiasm and pituitary. There are two main subtypes recognised in the WHO 2021 classification: adamantinomatous (mostly children, CTNNB1 mutation) and papillary (mostly adults, BRAF V600E mutation).

  • How does craniopharyngioma usually present?

    The classic picture is a combination of headache, visual field loss (often bitemporal hemianopia), and hormonal problems. Children often show growth failure and delayed puberty. Adults may have fatigue, low libido, amenorrhoea or subtle cognitive change. Diabetes insipidus (extreme thirst and high urine output) and hypothalamic obesity can also feature.

  • How is it diagnosed?

    MRI with gadolinium is the gold standard and shows a mixed solid, cystic and calcified suprasellar mass. CT is useful for confirming calcification. A full pituitary hormone panel, formal visual field testing and neuropsychology baseline complete the assessment. Care is coordinated through a specialist neuro-oncology and pituitary MDT.

  • Is surgery always the first treatment?

    Surgery is usually the mainstay when the tumour is resectable, but the goal has shifted. Gross total resection is often impossible without damaging the hypothalamus, so a planned partial resection followed by radiotherapy is increasingly preferred to preserve function. Transsphenoidal endoscopic surgery is used for smaller lesions and transcranial surgery for larger, complex tumours.

  • Why is proton beam therapy important for children?

    Proton beam therapy delivers a very focused radiation dose and dramatically reduces the dose to nearby healthy structures such as the hypothalamus, hippocampus and pituitary. In children this helps preserve neurocognition and endocrine function and lowers the long-term risk of secondary tumours. In the UK it is delivered at UCLH in London and The Christie in Manchester through the national commissioned service.

  • What can be done about hypothalamic obesity?

    Hypothalamic obesity is one of the hardest complications to manage and is resistant to standard lifestyle interventions. Options include GLP-1 receptor agonists such as semaglutide or tirzepatide, careful use of bariatric surgery in selected patients, and setmelanotide (Imcivree), an MC4R agonist approved in the US for acquired hypothalamic obesity and under review in the UK. Specialist obesity, endocrine and neuro-oncology input is essential.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.